PREMIERE DATE: May 20, 2018
EXPIRATION DATE: November 20, 2019
This activity offers CE credit for:
1. Physicians (CME)
All other clinicians either will receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
To recognize the issues associated with using the MAT (medication-assisted treatment) protocol for opioid use disorder.
At the end of this CE activity, participants should be able to:
• Evaluate the pros and cons of each of the three medications available in MAT
• Rationalize the need for long-term treatment for best outcomes
• Understand the clinical management of opioid use disorder
• Explain the barriers associated with the use of MAT
This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.
CME Credit (Physicians): This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process.
The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Arthur Robin Williams, MD, MBE, reports that his work is funded by NIDA grant #K23DA044342, “Improving the treatment cascade of MAT initiation and retention for opioid use disorder.” He also receives research funding from the Smithers Foundation. He reports no conflicts of interest.
Steve Koh, MD (peer/content reviewer), he has no disclosures to report.
Applicable Psychiatric Times staff and CME Outfitters staff, have no disclosures to report.
UNLABELED USE DISCLOSURE
Faculty of this CME/CE activity may include discussion of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity?
Call us at 877.CME.PROS (877.263.7767)
Dr Williams is Assistant Professor of Psychiatry, Division on Substance Use Disorders, Columbia University Medical Center, and Research Scientist, New York State Psychiatric Institute.
1. National Vital Statistics System. Provisional counts of drug overdose deaths as of 8/6/2017. National Center for Health Statistics, Centers for Disease Control and Prevention. 2017.
2. Ruhm CJ. Geographic variation in opioid and heroin involved drug mortality rates. Am J Prev Med. 2017; 53:745-753.
3. Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2013. HHS Publication No. (SMA) 14-4890;2014 Rockville, MD.
4. Cicero TJ, Ellis M, Kasper ZA. Increased use of heroin as an initiating opioid of abuse. Addict Behav. 2017; 74:63-66.
5. Williams AR, Bisaga A. From AIDS to opioids- how to respond to an epidemic. N Engl J Med. 2016; 375:813-815.
6. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357: j1550:1-14.
7. Amato L, Davoli M, Perucci CA, et al. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. J Sub Abuse Treat. 2005;28:321–329.
8. Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicenter, open-label, randomize controlled trial. Lancet. 2017. published online November 14, 2017. http://dx.doi.org/10.1016/S0140-6736(17)32812-X
9. Fullerton C, Kim M, Thomas CP. Medication-assisted treatment with methadone assessing the evidence. Psych Services. 2014;65(2)146-157.
10. D’Onofrio G, Chawarski MC, O’Connor PG, et al. Emergency department–initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2017;28;313:1636-1644.
11. Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016; 374:1232-1242.
12. McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689-1695.
13. Baser O, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011;17(Suppl 8):S235-S248.
14. Timko C, Schultz NR, Cucciare MA, et al. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016; 35:1,22-35.
15. Wu L, Zhu H, Swartz MS. Treatment utilization among persons with opioid use disorder in the United States. Drug Alcohol Depend. 2016;169:117-127.
16. Williams AR, Nunes EV, Olfson M. To battle the opioid overdose epidemic, deploy the “Cascade of Care” model. Health Affairs blog. March 13, 2017.
17. American Society for Addiction Medicine. Advancing access to addiction medications: Implications for opioid addiction treatment. Chevy Chase, Maryland. 2013:1-221.